METHODS FOR REDUCING INTERFERENCES

Abstract

The present invention relates to a method for determining an analyte in a sample suspected to comprise said analyte, comprising a) contacting with said sample at least a first and a second capture compound for said analyte, wherein said first and second capture compounds are nonidentical capture compounds, and wherein said capture compounds compete in binding to said analyte; b) contacting said capture compounds contacted with said sample with a specifier, wherein said specifier competes in binding to said capture compounds with said analyte; c) determining the amount of complexes comprising said specifier and a capture compound; and d) determining said analyte in a sample based on the result of step c). The present invention further relates to a method for improving the specificity of an indirect immunoassay for determining an analyte, comprising replacing at least 10% of a capture compound by a non-identical capture compound; wherein the capture compound replaced competes in binding to said analyte with the capture compound introduced. The present invention further relates to kits, devices, and uses related to the aforementioned methods.

Claims

1-13. (canceled)

14. A kit for detecting an analyte in a sample, comprising (i) at least two non-identical capture compounds for said analyte, or (ii) at least two non-identical detector compounds for said analyte, wherein said at least two non-identical capture compounds or detector compounds are non-identical polypeptides differing in at least one property selected from the group consisting of amino acid sequence, glycosylation, three-dimensional folding and/or conformation, and length of polypeptide chain, and wherein said at least two non-identical capture compounds or detector compounds compete in binding to said analyte.

15. The kit of claim 14, wherein said at least two non-identical capture compounds or said at least two non-identical detector compounds comprise the same analyte binding domain.

16. The kit of claim 14, wherein said kit comprises at least two non-identical capture compounds.

17. The kit of claim 16, wherein said at least two non-identical capture compounds have amino acid sequences sharing at least 70% sequence identity.

18. The kit of claim 16, wherein said at least two non-identical capture compounds are bound to a solid surface or are adapted to be bound to a solid surface.

19. The kit of claim 16, wherein said kit further comprises at least one antibody forming capture complexes with said at least two capture complexes.

20. The kit of claim 19, wherein said at least one antibody is bound to a solid surface or is adapted to be bound to a solid surface.

21. The kit of claim 16, wherein said at least two non-identical capture compounds are direct ligands of said analyte.

22. The kit of claim 14, wherein said kit comprises of from 2 to 10 capture compounds for said analyte, in an embodiment of from 2 to 5 capture compounds for said analyte, in an embodiment of from 2 to 4 capture compounds, in an embodiment of from 2 to 3 capture compounds, for said analyte.

23. The kit of claim 16, wherein said kit further comprises a specifier.

24. The kit of claim 23, wherein said specifier comprises the substructure of the analyte bound by the at least two non-identical capture compounds, bonded to an indicator.

25. The kit of claim 23, wherein the specifier consists of the analyte covalently bonded to an indicator.

26. The kit of claim 14, wherein said kit comprises at least two non-identical detector compounds, said detector compounds each comprising said analyte binding domain and an indicator.

27. The kit of claim 26, wherein said at least two non-identical detector compounds have amino acid sequences sharing at least 70% sequence identity.

28. The kit of claim 26, wherein said at least two non-identical detector compounds comprise the same indicator.

29. The kit of claim 26, wherein said indicator has a detectable property selected from the group consisting of an optical property, an enzymatic property, and a property of emitting radioactivity.

30. The kit of claim 26, wherein said at least two non-identical detector compounds are direct ligands of said analyte.

31. The kit of claim 14, wherein said kit comprises of from 2 to 10 detector compounds for said analyte, in an embodiment of from 2 to 5 detector compounds for said analyte, in an embodiment of from 2 to 4 detector compounds, in an embodiment of from 2 to 3 detector compounds, for said analyte.

32. The kit of claim 14, wherein said at least two non-identical capture compounds or said at least two non-identical detection compounds do not compete in binding to an interfering compound.

33. The kit of claim 14, wherein a first capture compound or a first detector compound comprises an amino acid sequence at least 70% identical to SEQ ID NO:1, and/or wherein a second capture compound or a second detector compound comprises an amino acid sequence at least 70% identical to SEQ ID NO:2.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0149] FIGS. 1A-1H schematically indicate the principle of the present invention as applied to a competitive assay; a: analyte, s: specifier, c1: capture compound 1, c2: capture compound 2, i1: interfering agent 1, i2: interfering agent 2. FIG. 1A) In the absence of the analyte, the specifier binds to capture compound 1. FIG. 1B) In the presence of the analyte, the analyte binds to capture compound 1 and prevents the specifier from binding to capture compound 1. FIG. 1C) In the presence of interfering agent 1, having affinity to capture compound 1 (but not to capture compound 2), interfering agent 1 binds to capture compound 1, thus preventing the specifier from binding. FIG. 1D) In the presence of interfering agent 2, having affinity to capture compound 2 (but not to capture compound 1), interfering agent 2 does not bind to capture compound 1, thus permitting the specifier to bind to capture compound 1. Conversely, FIG. 1E) interfering agent 1, having affinity to capture compound 1 (but not to capture compound 2), does not bind to capture compound 2, thus permitting the specifier to bind to capture compound 2; and FIG. 1F) interfering agent 2 does bind to capture compound 2, thus preventing the specifier from binding. (FIGS. 1G) and 1H)) in case capture compound 1 and 2 are used e.g. at a 1:1 ratio, the false signal reduction induced by interfering agent 1 or interfering agent 2 will be reduced to approximately 50%.

[0150] FIGS. 2A & 2B schematically show the test principle of a competitive test for anti-Hepatitis core (HBc) antigen antibodies. HBc: Hepatitis B core antigen; α-HBc: anti-HBc antigen antibody; the non-conjugated α-HBc antibody depicted with a double circumference is an antibody potentially present in a sample from a patient, the conjugated antibodies depicted with a single circumference are α-HBc antibodies added during the assay; conjugation is either with Ru: Ruthenium-complex, or bio: biotin; strp: streptavidin-coating of a solid support. FIG. 2A) in the absence of the analyte (a-HBc antibody), both, Ru-conjugated and bio-conjugated α-HBc antibodies can bind to HBc added to the assay mixture. Via the bio-strp-interaction, the complex is bound to a solid support and after washing, a signal generated from the Ru-conjugation can be measured. FIG. 2B) in the presence of the analyte (a-HBc antibody), the α-HBc-bio antibody and Ru-conjugated antibody are prevented from binding to HBc added to the assay mixture, thus preventing binding of a complex to the solid support. Accordingly, after washing, no signal can be generated from the Ru-complex, since this will be washed off. In FIGS. 2A & 2B, HBc as well as the α-HBc-bio conjugate are part of the capture compound complex.

[0151] FIGS. 3A-3H schematically indicates the principle of the present invention as applied to a double-antigen sandwich (DAGS) format. a: analyte, d: detector compound, c1: capture compound 1, c2: capture compound 2, i1: interfering agent 1, i2: interfering agent 2. FIG. 3A) in the absence of analyte, no analyte is bound to capture compound 1 (or 2) fixed on a solid support and, thus, the detector compound will be washed away in washing steps. FIG. 3B) in the presence of the analyte, e.g. an antibody, the analyte binds to capture compound 1 and to the detector compound, thus mediating binding of the detector compound to the solid surface. FIG. 3C) in the presence of interfering agent 1, which binds to capture compound 1 and to the detector compound, but not to capture compound 2, the detector compound becomes fixed to the solid support via the interaction with interfering agent 1. FIG. 3D) in the presence of interfering agent 2, which binds to capture compound 2 and to the detector compound, but not to capture compound 1, the detector compound is not fixed to the solid support via interfering agent 1. Conversely, FIG. 3E) in the presence of interfering agent 1, the detector compound is not fixed to the solid support via the interaction with interfering agent 2; and FIG. 3F) in the presence of interfering agent 2, the detector compound will be fixed to the solid support via capture compound 2. (FIGS. 3G) and 3H)) in case capture compound 1 and 2 are used e.g. at a 1:1 ratio, the false signal increase induced by interfering agent 1 or interfering agent 2 will be reduced to approximately 50%. A scheme could mutatis mutandis be drawn for the use of two non-identical detector compounds.

EXAMPLES

Example 1

[0152] Cloning and Purification of Recombinant Hepatitis B Core Antigen

[0153] The synthetic gene encoding the Hepatitis B core antigen (HBcAg) was purchased from Eurofins MWG Operon (Ebersberg, Germany). On the basis of the pET24a expression plasmid of Novagen (Madison, Wis., USA) the following cloning steps were performed. The vector was digested with BamH1 and Xho1 and a cassette comprising the HBcAg was inserted. The insert of the resulting plasmid was sequenced and found to encode the desired protein. The amino acid sequence of the resulting protein is shown in the sequence protocol of the present invention. The recombinant HBcAg did not contain a C-terminal hexahistidine tag.

[0154] The recombinant HBcAg was purified according to the following protocol. E. coli BL21 (DE3) cells harboring the expression plasmid were grown in LB medium plus kanamycin (30 μg/ml) to an OD600 of 1, and cytosolic overexpression was induced by adding isopropyl-β-D-thiogalactosid (IPTG) to a final concentration of 1 mM at a growth temperature of 37° C. 4 hours after induction, cells were harvested by centrifugation (20 min at 5000×g), frozen and stored at −20° C. For cell lysis, the frozen pellet was resuspended in 25 mM sodium phosphate pH 8.5, 6 mM MgCl2, 10 Um′ Benzonase®, 1 tablet Complete® and 1 tablet Complete® EDTA-free per 50 ml of buffer (protease inhibitor cocktail) and the resulting suspension was lysed by high pressure homogenization. The crude lysate was centrifuged and the HBcAg in the supernatant was precipitated with ammonium sulfate (35% w/v).

[0155] After additional centrifugation the precipitate was resuspended and dialyzed against a phosphate buffer followed by a heating step (70° C. for 30 minutes). After centrifugation the clear supernatant was applied onto a Toyopearl DEAE 650-11 column (from Tosoh Bioscience) pre-equilibrated in 25 mM potassium phosphate pH 7. The protein was then eluted by applying a gradient up to a potassium chloride concentration of 500 mM. Finally, the protein was subjected to size exclusion chromatography (S400) and the protein-containing fractions were pooled.

Example 2

[0156] Immunoassay for Detecting Anti-HBc Antibodies in a Competitive Test Format

[0157] Serum samples from a panel of healthy blood donors were analyzed in a competitive Anti-HBc ECLIA (Electrochemiluminescence Immunoassay) for the presence of anti-HBc antibodies in automated Cobas e® analyzers (Roche Diagnostics GmbH). Cobas e® and Elecsys® are registered trademarks of the Roche group. The samples were tested negative for Anti-HBc with at least one CE-marked Anti-HBc assay that is different from the Elecsys® Anti-HBc assay and which is commercially available.

[0158] In the assay, serum is reacted with HBc. After addition of biotinylated antibodies and ruthenium complex (Tris(2,2′-bipyridyl)ruthenium(II)-complex; (Ru(bpy)32+)-labeled antibodies, both specific for HBcAg, together with streptavidin-coated microparticles, the still-free binding sites on the HBc-antigens become occupied. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin. After removal of unbound substances, a voltage is applied to the electrode and induces chemiluminescent emission at 620 nm after excitation at a platinum electrode which is measured by a photomultiplier.

[0159] High measured values indicate binding of biotinylated antibodies and ruthenium complex-labeled antibodies added and, thus, absence of anti-HBc antibodies in the sample. In the presence of anti-HBc antibodies in the sample these antibodies compete with both types of assay specific antibodies for binding to the antigen HBcAG leading to reduced light emission at 620 nm after excitation at a platinum electrode. The signal output is in arbitrary light units.

[0160] Accordingly, samples having a measured value of higher than the cut-off index 1.0 are considered non-reactive, whereas samples having a measured value lower than or equal to the cut-off index 1.0 are considered reactive.

[0161] Based on the competitive Elecsys® Anti-HBc assay format three different HBcAg settings were tested. “HBcAg X” refers to an antigen comprising SEQ ID NO:2; “HBcAg Y” refers to an antigen comprising SEQ ID NO:1. Only the antigen setting was modified, all other reagent and conditions remained unchanged. The results of true positive (infected) samples was not affected by applying a combination of HBcAg X and Y as first and second capture compound (data not shown). Table 1 relates only to discrepant (=false) positive results of the sample panel. The three different settings were as follows:

[0162] A) HBcAg X is used as target in the competitive Anti-HBc assay.

[0163] B) HBcAg Y (slightly different from HBcAg X) is used as target in the competitive Anti-HBc assay.

[0164] C) A combination of HBcAg X and HBcAg Y are used together as target in the competitive anti-HBc assay

[0165] Table 1 shows the results of a competitive Anti-HBc-ECLIA (Electrochemiluminescence Immunoassay). Commercially available sera (Bavarian Red Cross) negative for antibodies against HBc antigen were used as samples. Table 1 lists only those results with discrepant findings. Different HBcAG showed individual patterns of discrepant positive Anti-HBc results. When two different preparations of HBc-antigen (HBcAG) were used, 11 samples were tested (false-) positive (reactive) when HBcAG X was used, 7 samples tested (false-) positive only when the second HBcAG Y was used, and 2 samples tested (false)-positive with both HBcAG X and with HBcAG Y. In contrast, when a 1:1 mixture of both antigens, i.e. HBcAG X and HBcAG Y was used, only 5 of these 18 samples tested positive, decreasing the number of false-positive tests by more than 3-fold. In detail, the number of samples tested false-positive using HBcAGX only, was reduced from 11 to 3 and the number of samples tested false-positive using HBcAGY only, was reduced from 9 to 5 when said 1:1 mixture of both antigens (HBcAG X and HBcAG Y) was used. As expected, the two samples tested false-positive with both antigens (Samples No. 2942 and 3657), also tested false-positive with the mixture.

[0166] As a consequence, the specificity of this competitive immunoassay was increased when at least two slightly different HBc antigens were applied as a mixture.

[0167] By applying the principle of using two slightly different first and second capture compounds for an analyte in a method based on a competitive test format the specificity can be considerably increased, i.e. false positive results can be avoided to a considerable extent.

TABLE-US-00001 TABLE 1 Results of a competitive Anti-HBc ECLIA (Electrochemiluminescence Immunoassay), COI: Cut-off index HBcAG Mix Interpretation HBcAG X HBcAG Y X + Y reactive COI ≤ 1.0 COI ≤ 1.0 COI ≤ 1.0 non-reactive COI > 1.0 COI > 1.0 COI > 1.0 Sample No. COI COI COI Anti-HBcAG X 1984 0.234* 2.19 1.19 interference 2942 0.463* 0.462* 0.396* 3180 0.582* 1.37 0.976* 3633 0.639* 2.17 1.29 3470 0.788* 2.26 1.38 3784 0.820* 2.17 1.47 2426 0.865* 1.53 1.06 3657 0.878* 0.984* 0.858* 3976 0.891* 2.34 1.41 2423 0.927* 2.16 1.52 2905 0.990* 2.22 1.51 Anti-HBcAG Y 2858 1.66 0.185* 0.941* interference 3813 1.59 0.311* 1.07 1344 1.39 0.428* 0.910* 2038 2.05 0.473* 1.21 2898 2.03 0.754* 1.38 1529 1.83 0.800* 1.34 2263 1.56 0.840* 1.20 Anti-HBc 2243 1.84 2.26 2.09 negative 2269 1.94 2.26 2.04 2155 2.02 2.26 2.13 1311 1.98 2.26 2.08 1065 2.01 2.26 2.26 *Discrepant 11 9 5 positive samples [n]